|
"Long
before it's in the papers"
August 03, 2010
RETURN
TO THE WORLD SCIENCE HOME PAGE
Pot may be both good and bad, researchers say
Nov. 25, 2006
Special to World Science
For scientists, as for society at large, marijuana has been among the most bedeviling of drugs.
Some studies have found that the illicit substance damages the memory. Others suggest that it doesn’t, or even that it’s beneficial for some conditions, including
Alzheimer’s disease. Through it all, the public clamors for answers—desperately needed to resolve a decades-long, raucous debate over whether pot is safe enough to be legal.
|
|
Leaves of the marijuana
or Cannabis sativa plant (courtesy Iowa Dept. of Public Safety)
|
A theory now emerging from a research group proposes that the truth may be more complex than either side in that debate would have us believe. Marijuana may have played a trick on us all, they suggest,
by playing the roles of both health villain and hero.
In hefty doses, they argue, its active ingredient may protect the brain
against various types of damage, whereas in tiny doses, harmful
effects would come through.
The bad doses would be much lower than those normally obtained from smoking a
“joint,” argues Yosef Sarne of Tel Aviv University in Israel, a member of the research team. On the other hand, he
notes, a large dose inevitably becomes a small one as the body slowly
clears it out—so perhaps a user can never sidestep the dangers completely.
Sarne and five colleagues at the university presented findings in support
of their hypothesis in the Nov. 6 issue of the research journal Neuroscience Letters.
The active compound responsible for marijuana’s “high”
is called delta nine tetrahydrocannabinol, or THC. This and related compounds, in high doses, tend to restrict the release of a chemical called glutamate from brain cells, Sarne and colleagues argued. This
effect can be helpful because excess release of glutamate—which
is also an essential chemical messenger in the brain—is implicated in various disorders, including Alzheimer’s.
This, the scientists wrote, may explain why THC-like compounds, called
cannabinoids, help protect brain cells in cases such as ischemia, or blocked blood vessels; excitotoxicity, or
overstimulation of nerve cells; and even physical injuries.
Studies suggest cannabinoids temper glutamate release by partially blocking molecular gateways in nerve cells, known as voltage-dependent calcium channels, Sarne and colleagues wrote.
But ultra-low doses appear to have the opposite effect, they added.
Thus they proposed that “an acute treatment results in a high concentration of the drug close to the time of trauma and therefore protects the brain from the acute insult, while chronic treatment exposes the organism to low concentrations of
cannabinoids for long periods of time.” During that time, “minor” nerve cell damage accumulates.
In the study, Sarne and colleagues injected mice with THC doses that they said were some 1,000 times lower than what humans would get from smoking a
joint, taking into account body weight. The treatment significantly worsened the rodents’ performance on maze tests three weeks later, compared to untreated mice, they wrote.
Exactly how the chemical damages the brain remains unclear, Sarne’s team wrote, as are the implications for humans.
“Human subjects may overcome such minor deficits,” they wrote. Some brain imaging studies have found that frequent smokers “can compensate for subtle cognitive deficits by enlisting larger brain regions or by recruiting additional brain areas.... Yet, such subtle deficits might emerge under certain behavioral or physiological conditions.”
The importance of this research goes “beyond its scientific significance,” the team wrote in a previous paper, published in the journal
Medical Hypotheses in 2004. “Cannabinoids are the most widely used drugs of abuse. In spite of the many reports on their long-term neurotoxic effects,
cannabinoids are still considered by many as ‘safe soft drugs,’” and their beneficial effects are often cited to back up claims for their long-term safety.
Distinguishing these two modes of action may help educate the public as to
pot’s unhealthy consequences, while clarifying the clinical benefits,
they wrote. Cannabinoids are used or under consideration for use, they noted, to fight pain and inflammation,
to prevent vomiting and nausea from chemotherapy, to stimulate appetite in AIDS and anorexia patients, and to treat muscle spasms
in multiple sclerosis.
* * *
Send us a comment
on this story, or send
it to a friend
|
|
|
On
Home Page
LATEST
EXCLUSIVES
-
Report: cells “from space” have unusual makeup
-
Dolphins and the evolution of teaching
-
Drug may trick body into “thinking” you exercised
-
Tit-for-tat: birds found to repay wartime help
-
Musical genes may be coming to light
MORE NEWS
-
Rock-hurling zoo chimp stocked ammo in advance: study
-
Faith found to reduce errors on psychological test
-
Doodling gets its due: tiny artworks may aid memory
-
From oral to moral? Dirty deeds may prompt “bad taste” reaction
|
|
|
|
|
|

It's true, pot may have many benefits as well as downsides. Learn
about marijuana and see why people are eager to dive into research to
show how it can be used to benefit people with health ailments. Medicinal
marijuana is a topic that is becoming more and more prominent so catch
up on the latest news and issues associated with it.
|
|
|
| |
|
|
|
|
|
For researchers, as for society at large, marijuana has been among the most bedeviling of drugs.
Some studies have found that the illicit substance damages the memory. Others suggest that it doesn’t, or even that it may be beneficial for some conditions including Alzheimer’s disease. Through it all, the public clamors for answers—desperately needed to help resolve a decades-long, raucous debate over whether pot is safe enough to be legalized.
A group of scientists now proposes that the answer may be more complex than either side in that debate would have us believe. Marijuana may have played a trick on us all, they suggest, playing the roles of both health villain and hero.
In hefty doses, they argue, its active ingredient may help protect the brain against various types of damage.
But in tiny doses, harmful effects come through, they add. Those damaging doses would be much lower than those normally taken in from smoking in a marijuana cigarette, argues Yosef Sarne of Tel Aviv University in Israel, a member of the research team. On the other hand, he adds, a large dose inevitably becomes a small one as the body clears it out—so perhaps a user can never sidestep the dangers completely.
The team presented its findings in the Nov. 6 issue of the research journal Neuroscience Letters.
The active compound that produces the “high” in marijuana is called delta nine tetrahydrocannibanol, or THC for short. This and related compounds, in high doses, tend to restrict the release of a chemical called glutamate from brain cells, Sarne and colleagues argued. This can be helpful because excess release of glutamate—otherwise a normal and essential chemical messenger in the brain—is implicated in various disorders, including Alzheimer’s.
This may explain why compounds in the THC family, called cannabinoids, help protect brain cells in cases such as ischemia, or blocked blood vessels; excitotoxicity, or overstimulation of nerve cells; or blows to the head.
Studies suggest that cannabinoids seem to suppress glutamate release by partially blocking molecular gateways in nerve cells, known as voltage-dependent calcium channels, Sarne and colleagues wrote. But ultra-low doses appear to have the opposite effect, they added.
Thus the researchers hypothesized that “an acute treatment results in a high concentration of the drug close to the time of trauma and therefore protects the brain from the acute insult, while chronic treatment exposes the organism to low concentrations of cannabinoids for long periods of time.” During that time, “minor” nerve cell damage accumulates.
In the Neuroscience Letters study, Sarne and colleagues injected mice with THC doses that they said were some 1,000 times lower, taking into account body weight, than what humans would get from smoking a joint. The treatment significantly worsened the rodents’ performance on maze tests three weeks later, compared to untreated mice, they wrote.
Exactly how the chemical damages the brain remains unclear, Sarne’s team wrote, as are the implications for humans.
“Human subjects may overcome such minor deficits,” they wrote. Some brain imaging studies have found that frequent smokers “can compensate for subtle cognitive deficits by enlisting larger brain regions or by recruiting additional brain areas.... Yet, such subtle deficits might emerge under certain behavioral or physiological conditions.”
The importance of this research goes “beyond its scientific significance,” the team wrote in a previous paper, published in the journal Medical Hypotheses in 2004. “Cannabinoids are the most widely used drugs of abuse. In spite of the many reports on their long-term neurotoxic effects, cannabinoids are still considered by many as ‘safe soft drugs,’” and their beneficial effects are often cited to back up claims for their long-term safety.
“The clear dissociation between these two modes of action, and the demonstration that cannabinoids induce long-term cognitive deficits, may help to draw the public awareness to the deleterious consequences” of chronic pot use, as well as clarifying the drug’s clinical benefits. Cannabinoids are used or under consideration for use, they noted, to fight pain and inflammation, prevent vomiting and nausea from chemotherapy, stimulate appetite in AIDS and anorexia patients, and to treat muscle spasms associated with multiple sclerosis.
|